Industry Reports
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Peregrine Pharmaceuticals, Inc announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred...
Press Releases
Peregrine Pharmaceuticals Updates Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55...
Press Releases
EU approves Novartis drug Afinitor to treat certain types of advanced GI and lung NET
Novartis announced that the EU has approved Afinitor®(everolimus) tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine...
Press Releases
Mylan NV launches generic version of Celgenes Vidaza injection
Mylan N.V. announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan...
News
AbbVies Research Commitment to Helping People Living with Rheumatologic Diseases Highlighted Annual EULAR 2016
AbbVie a global biopharmaceutical company announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for...
News
GlaxoSmithKline plans to file NDA in U.S. for FF/UMEC/VI in patients with COPD
GlaxoSmithKline plc and Innoviva, Inc announced that, following discussions with the US FDA ,GSK has brought forward the plan to file a NDA in...
News
Biogens Investigational Alzheimers Disease Treatment Aducanumab Accepted into European Medicines Agencys PRIME Program
Biogen announced that aducanumab, its investigational treatment for early Alzheimer’s disease (AD), was accepted into the European Medicines Agency’s (EMA) Priority Medicines (PRIME) program....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read